Home › Cases › Thrombotic Thrombocytopaenic Purpura
TTP
Thrombotic Thrombocytopaenic Purpura
6 questions
Question 1 · Recognition
Correct answer: Thrombotic thrombocytopaenic purpura (TTP)
Why
This presentation is classic for TTP, characterised by the pentad: Microangiopathic haemolytic anaemia (MAHA — schistocytes on film, elevated LDH, elevated bilirubin, low Hb), Thrombocytopenia, Neurological features (confusion), Renal impairment, and Fever. Not all five features need be present — MAHA + thrombocytopenia alone should prompt consideration of TTP. The markedly elevated LDH reflects haemolysis and tissue ischaemia. DIC is less likely here because the PT and APTT are typically normal in TTP — the coagulopathy screen would be required to differentiate. ITP causes isolated thrombocytopenia without haemolysis. This is a haematological emergency — TTP without treatment has >90% mortality.
Key point
Suspect TTP with MAHA + thrombocytopenia — the full pentad (MAHA, low platelets, neuro, renal, fever) is not required to act; schistocytes + low platelets + elevated LDH should prompt emergency treatment.
Question 2 · Differentiating TTP from HUS and DIC
Correct answer: Normal PT/APTT supports TTP or HUS over DIC — HUS is distinguished by prominent renal failure with less neurological involvement
Why
The key differentiating feature is the coagulation screen: in TTP and HUS, PT and APTT are normal because the pathology is platelet-mediated microvascular thrombosis (not coagulation factor consumption). In DIC, PT and APTT are prolonged with low fibrinogen and elevated D-dimer. HUS (haemolytic uraemic syndrome) shares MAHA and thrombocytopenia with TTP but is typically: associated with Shiga toxin-producing E. coli (STEC) infection (diarrhoeal prodrome), more common in children, and dominated by acute kidney injury with relatively preserved neurology. Atypical HUS (aHUS) is complement-mediated and lacks the diarrhoeal prodrome. TTP is more often neurologically prominent. In adults without a diarrhoeal prodrome, treat as TTP until proven otherwise.
Key point
Normal PT/APTT distinguishes TTP/HUS from DIC — in TTP, neurological features predominate; in HUS, renal failure dominates and a diarrhoeal prodrome (STEC) is typical in children.
Question 3 · ADAMTS13 Assay
Correct answer: ADAMTS13 is a von Willebrand factor-cleaving metalloprotease — activity <10% with inhibitor confirms immune TTP
Why
ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 motifs, member 13) is the von Willebrand factor (VWF)-cleaving protease. Normally it cleaves ultra-large VWF multimers released from endothelium into smaller, less prothrombotic units. In immune TTP (iTTP), autoantibodies (IgG inhibitors) directed against ADAMTS13 cause its deficiency — activity falls to <10% (often undetectable). The resulting accumulation of ultra-large VWF multimers causes platelet aggregation and microvascular thrombosis. Importantly, do not wait for the ADAMTS13 result before starting treatment — it takes days to return and TTP is immediately life-threatening. ADAMTS13 <10% + inhibitor confirms iTTP; hereditary TTP (Upshaw-Schulman syndrome) shows low ADAMTS13 without an inhibitor.
Key point
ADAMTS13 activity <10% with an IgG inhibitor confirms immune TTP — but do NOT delay treatment waiting for this result; send the sample and start plasma exchange immediately.
Question 4 · Emergency Plasma Exchange
Correct answer: Daily plasma exchange (PEX) using fresh frozen plasma as replacement fluid
Why
Plasma exchange (PEX / plasmapheresis) with fresh frozen plasma (FFP) as replacement fluid is the cornerstone of acute TTP treatment and should be initiated within 4-6 hours of diagnosis. PEX works by two mechanisms: (1) removing the ADAMTS13 inhibitor (autoantibody) and any pathological ultra-large VWF multimers, and (2) replacing functional ADAMTS13 from donor FFP. If PEX cannot be initiated immediately (e.g. awaiting line placement), FFP infusion should be given as a temporising measure. PEX is continued daily until platelet count is >150 ×10⁹/L for two consecutive days, LDH normalises, and neurological features resolve. Without PEX, mortality from TTP exceeds 90% — with treatment, it falls to approximately 10-20%.
Key point
Daily plasma exchange with FFP is the emergency treatment for TTP — start within 4-6 hours; if PEX unavailable, give FFP infusion as a bridge while arranging transfer.
Question 5 · Why Platelet Transfusion is Dangerous
Correct answer: Disagree — platelet transfusion in TTP can precipitate life-threatening thrombosis and is contraindicated except to cover life-threatening haemorrhage
Why
Platelet transfusion is contraindicated in TTP and is described as 'adding fuel to the fire.' In TTP, platelets are consumed by ongoing microvascular thrombosis driven by ultra-large VWF multimers — transfusing additional platelets simply provides more substrate for this process, dramatically worsening microvascular thrombosis. This can precipitate stroke, myocardial infarction, mesenteric ischaemia, and death. Multiple case reports and series document catastrophic deterioration following platelet transfusion in TTP. Platelet transfusion should only be considered in TTP if there is immediately life-threatening haemorrhage (e.g. intracranial bleed) and must be discussed with haematology first. The thrombocytopenia in TTP is a consequence of the disease — treat the disease, not the count.
Key point
Never give platelets in TTP — this is 'adding fuel to the fire' and can cause catastrophic arterial thrombosis (stroke, MI); the thrombocytopenia resolves with plasma exchange.
Question 6 · Adjunct Therapies
Correct answer: High-dose corticosteroids (prednisolone 1 mg/kg/day) and caplacizumab to reduce VWF-mediated platelet aggregation
Why
Standard adjuncts to plasma exchange in immune TTP include: Corticosteroids (prednisolone 1 mg/kg/day orally or IV methylprednisolone) — reduce autoantibody production and ADAMTS13 inhibitor titre; used universally. Caplacizumab (a bivalent anti-VWF nanobody) — NICE-approved for acute iTTP (based on the HERCULES trial); blocks VWF-platelet interaction, rapidly reduces microvascular thrombosis, shortens time to platelet normalisation, and reduces TTP-related death. Rituximab (anti-CD20 monoclonal antibody) — targets B-cells producing the ADAMTS13 inhibitor; increasingly used in acute episodes to reduce relapse. Heparin is NOT routinely used and may worsen bleeding. Aspirin is avoided in thrombocytopenic patients. Folic acid supplementation is given for haemolysis.
Key point
Adjuncts to plasma exchange in iTTP: prednisolone 1 mg/kg, caplacizumab (NICE-approved nanobody blocking VWF), and rituximab to suppress the ADAMTS13 inhibitor and reduce relapse.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.